Advances in the Molecular Landscape of Lung Cancer Brain Metastasis

dc.contributor.authorSouza, Vanessa G. P. [UNESP]
dc.contributor.authorde Araújo, Rachel Paes [UNESP]
dc.contributor.authorSantesso, Mariana R. [UNESP]
dc.contributor.authorSeneda, Ana Laura [UNESP]
dc.contributor.authorMinutentag, Iael W. [UNESP]
dc.contributor.authorFelix, Tainara Francini [UNESP]
dc.contributor.authorHamamoto Filho, Pedro Tadao [UNESP]
dc.contributor.authorPewarchuk, Michelle E.
dc.contributor.authorBrockley, Liam J.
dc.contributor.authorMarchi, Fábio A.
dc.contributor.authorLam, Wan L.
dc.contributor.authorDrigo, Sandra A. [UNESP]
dc.contributor.authorReis, Patricia P. [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionBritish Columbia Cancer Research Institute
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.date.accessioned2023-07-29T13:41:24Z
dc.date.available2023-07-29T13:41:24Z
dc.date.issued2023-02-01
dc.description.abstractLung cancer is one of the most frequent tumors that metastasize to the brain. Brain metastasis (BM) is common in advanced cases, being the major cause of patient morbidity and mortality. BMs are thought to arise via the seeding of circulating tumor cells into the brain microvasculature. In brain tissue, the interaction with immune cells promotes a microenvironment favorable to the growth of cancer cells. Despite multimodal treatments and advances in systemic therapies, lung cancer patients still have poor prognoses. Therefore, there is an urgent need to identify the molecular drivers of BM and clinically applicable biomarkers in order to improve disease outcomes and patient survival. The goal of this review is to summarize the current state of knowledge on the mechanisms of the metastatic spread of lung cancer to the brain and how the metastatic spread is influenced by the brain microenvironment, and to elucidate the molecular determinants of brain metastasis regarding the role of genomic and transcriptomic changes, including coding and non-coding RNAs. We also present an overview of the current therapeutics and novel treatment strategies for patients diagnosed with BM from NSCLC.en
dc.description.affiliationMolecular Oncology Laboratory Experimental Research Unit Faculty of Medicine São Paulo State University (UNESP)
dc.description.affiliationBritish Columbia Cancer Research Institute
dc.description.affiliationDepartment of Neurology Psychology and Psychiatry Faculty of Medicine São Paulo State University (UNESP)
dc.description.affiliationFaculty of Medicine University of São Paulo
dc.description.affiliationDepartment of Surgery and Orthopedics Faculty of Medicine São Paulo State University (UNESP)
dc.description.affiliationUnespMolecular Oncology Laboratory Experimental Research Unit Faculty of Medicine São Paulo State University (UNESP)
dc.description.affiliationUnespDepartment of Neurology Psychology and Psychiatry Faculty of Medicine São Paulo State University (UNESP)
dc.description.affiliationUnespDepartment of Surgery and Orthopedics Faculty of Medicine São Paulo State University (UNESP)
dc.identifierhttp://dx.doi.org/10.3390/cancers15030722
dc.identifier.citationCancers, v. 15, n. 3, 2023.
dc.identifier.doi10.3390/cancers15030722
dc.identifier.issn2072-6694
dc.identifier.scopus2-s2.0-85147865141
dc.identifier.urihttp://hdl.handle.net/11449/248346
dc.language.isoeng
dc.relation.ispartofCancers
dc.sourceScopus
dc.subjectbrain metastasis
dc.subjectcoding and non-coding RNAs
dc.subjectlung cancer
dc.subjectmicroenvironment
dc.subjectmolecular mechanisms
dc.subjecttherapeutic strategies
dc.titleAdvances in the Molecular Landscape of Lung Cancer Brain Metastasisen
dc.typeResenha
unesp.author.orcid0000-0002-1561-1651[1]
unesp.author.orcid0000-0003-0712-8739[2]
unesp.author.orcid0000-0001-9740-1780[3]
unesp.author.orcid0000-0003-3155-9088[6]
unesp.author.orcid0000-0001-6436-9307[7]
unesp.author.orcid0000-0001-6747-6642[12]
unesp.author.orcid0000-0003-3775-3797[13]

Arquivos